SCHEMBL277151

SCHEMBL277151

CCCCC/C(C(=O)O)=C(/N)CC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FNTA P49354 2/20 0.57
FNTB P49356 2/20 0.57
THRB P10828 1/20 0.57
PGGT1B P53609 1/20 0.57
AKR1B1 P15121 1/20 0.48
GPR84 Q9NQS5 7/20 0.46
PPARG P37231 7/20 0.46
PPARD Q03181 7/20 0.46
PPARA Q07869 7/20 0.46
HDAC11 Q96DB2 5/20 0.46
TSHR P16473 4/20 0.46
PTPN1 P18031 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TLR2 O60603 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
FABP4 P15090 2/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46
MEN1 O00255 1/20 0.46
ESR1 P03372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6545373 0.98 FNTA (0.60) FNTAFNTBTHRBPGGT1BAKR1B1
SCHEMBL2064793 0.94 FNTA (0.48) FNTAFNTBTHRBPGGT1BAKR1B1
SCHEMBL4152299 0.85 FFAR3 (0.42) FNTAFNTBTHRBPGGT1BAKR1B1
SCHEMBL4152302 0.85 FFAR3 (0.42) FNTAFNTBTHRBPGGT1BAKR1B1
SCHEMBL4152296 0.85 FFAR3 (0.42) FNTAFNTBTHRBPGGT1BAKR1B1
SCHEMBL183671 0.82 FNTA (0.71) FNTAFNTBTHRBPGGT1BAKR1B1
SCHEMBL555048 0.82 FNTA (0.71) FNTAFNTBTHRBPGGT1BAKR1B1
SCHEMBL555050 0.82 FNTA (0.71) FNTAFNTBTHRBPGGT1BAKR1B1
SCHEMBL13144808 0.81 FNTA (0.59) FNTAFNTBTHRBPGGT1BAKR1B1
SCHEMBL30007255 0.81 FNTA (0.64) FNTAFNTBTHRBPGGT1BGPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067586-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2011-11-29 US disclosed
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES HAYAKAWA MASAHIKO 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137584-A1 FUSED HETEROARYL DERIVATIVES PIK3CD, PIK3R3, PIK3C2A FNTA 1183/4885FNTB 1861/4885THRB 2794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.